Latest news with #AEX
Business Wire
10 hours ago
- Business
- Business Wire
Prosus Accelerates Growth and Profitability, with 12X Improvement in Ecommerce Adjusted EBIT and 100% Increase in Dividend
AMSTERDAM & JOHANNESBURG--(BUSINESS WIRE)--Prosus N.V. (Prosus) (AEX and JSE: PRX) delivered a strong performance during a transformative year. We have exceeded our profitability targets, as we build the leading lifestyle ecommerce company in Latin America, Europe and India, driven by AI and innovation. Ecommerce revenue growth of 21%, to US$6.2bn. Adjusted EBIT increased twelve times to US$443m, ahead of guidance. iFood aEBIT grew 178%, OLX aEBIT up 61% and eMAG achieved profitability. Free cash flow positive for the first time, excluding Tencent. 100% increase in dividend to €0.20. US$7.8bn 1 invested to strengthen our regional ecosystems and expand portfolio of AI-native startups. Buybacks 2 returned over US$50bn, driving 15% NAV per share accretion. Fabricio Bloisi, Prosus CEO, Prosus and Naspers said: 'Prosus is rapidly transforming into an operating technology company, focused on lifestyle ecommerce, and powered by innovation and collaboration. This past year, we announced two significant deals to strengthen our regional ecosystems. We completed the acquisition of Despegar in May 2025 and are already integrating its products into iFood's Clube membership. We are making good progress with the purchase of Just Eat which will create a new AI-powered tech champion in Europe. 'I believe that truly great companies are shaped by their culture. Through 'The Prosus Way', we've implemented a cultural model that empowers our teams to deliver exceptional customer experiences through discipline, innovation and adopting an AI-first mindset. In the face of unprecedented technological disruption, we are now more connected and innovative than ever before. I'm confident that our enhanced culture and ecosystem approach, powered by Prosus, will fuel our journey to create the next US$100bn in value.' Nico Marais, Prosus CFO, commented: 'Prosus has delivered a strong financial performance over the past year, with topline growth in our operating businesses at double the rate of our peers. Ecommerce profitability has improved meaningfully from US$38m in FY24, to aEBIT of US$443m, ahead of our guidance. We expect this momentum to continue, and to add at least the same level of incremental aEBIT in FY26. FY2025 marks the first year that Prosus is free cash flow positive, excluding the Tencent dividend, with a free cash flow improvement of US$513m. As our financial position strengthens, we're able to share more with our shareholders, and have proposed a 100% increase in our dividend, to €0.20. Our disciplined capital allocation and strong balance sheet positions us well to execute on our ecosystem strategy.' Group performance Peer-leading growth and accelerating profitability across Ecommerce portfolio Food Delivery: iFood delivers world-class performance, exceeding growth and profitability targets and drives innovation and ecosystem expansion iFood delivered strong top line growth, with Gross Merchandise Value (GMV) up 32%, orders up 29% and revenue increasing 30%. iFood's core food delivery business grew aEBIT by 71% to US$306m, improving aEBIT margin to 27%; performance driven by higher ad revenues, increased order frequency and retention driven by iFood's Clube loyalty programme, and investments in its merchant platform. iFood's growth initiatives grew revenue by 34%, driven by strong performance in its groceries marketplace and credit businesses. Overall, iFood achieved a record profit, with aEBIT of US$226m, up 178%. Delivery Hero grew GMV by 8% for FY24, with revenue up 24%, boosting profitability to an adjusted EBITDA of €693m (from €254m in FY23). From January to December 2024, Swiggy grew Gross Order Value (GOV) by 29%, while adjusted EBITDA losses reduced to US$182m, from US$261m in the prior year. In Q125, Swiggy delivered GOV growth of 40% year-on-year, and quick commerce GOV growth of 101% year-on-year, with 316 new dark stores added in the quarter. Classifieds – OLX Group: Strong performance, with a significant jump in profitability and expanding margins OLX consolidated revenue grew 18%, with standout performances by motors and real estate verticals. Motors and real estate grew revenue 24% and 23% respectively, through improved monetisation, innovative product development and new trust-building initiatives within motors, and product enhancements within real estate. aEBIT accelerated by 61% to US$270m, with aEBIT margin up 10pp, to 35%. Payments & Fintech – PayU: Strong topline growth and improving profitability, despite challenging market conditions India payments TPV 5 increased by 17%, and revenues by 14%; aEBIT loss of US$12m reflects increased competition, resulting in lower take rates. India payments achieved breakeven in H2. India credit grew its loan book by 19% and revenues by 63%; aEBIT loss of US$32m impacted by higher costs and increased consumer loan book losses. Iyzico grew revenues 87% to US$288m, while aEBIT of US$18m at a margin of 6% reflected rising interest rates and investments in strategic growth initiatives. Overall, PayU's aEBIT losses improved by >100% to US$11m. Etail: eMAG achieved target of overall profitability for FY25 Strong growth with GMV up 9%, and revenue up 12% to US$2.5bn. aEBIT improved by US$40m to US$14m; includes one-off costs in Hungary in H1. Improved performance due to good growth in Romanian etail, and emerging logistics and grocery businesses Please note: Group results are shown on a consolidated basis from continuing operations, which reflect all majority owned and managed businesses. All OLX Autos business units are classified as discontinued operations, in line with IFRS disclosures. All growth percentages shown here are in local currency terms, excluding the impact of acquisitions and disposals (M&A), unless otherwise stated. Growth percentages shown here for all non-financial key performance indicators compare FY25 to FY24. Expand For full details of the Group's results, please visit
Yahoo
6 days ago
- Business
- Yahoo
The Netherlands Associations for Investor Relations (NEVIR) announces the nominees for the 18th Annual Dutch IR Awards
Amsterdam, the Netherlands, June 12, 2025: The Netherlands Association for Investor Relations (NEVIR) is proud to announce the nominations for the 18th Annual Dutch IR nominees are: AEX Company of the Year ASML Holding ASR Nederland Shell AEX IR Professional of the Year Marcel Kemp, ASML Holding Michel Hulters, ASR Nederland Robin van den Broek, NN Group AMX Company of the Year CTP Just Eat Royal Vopak AMX IR Professional of the Year Rutger Relker, Aalberts Maarten Otte, CTP Fatjona Topciu, Royal Vopak AScX Company of the Year Alfen Avantium Wereldhave AScX IR Professional of the Year Aarne Luten, Avantium Floor van Maaren, ForFarmers Inge Laudy, PostNL Best ESG Engagement ASR Nederland Royal Ahold Delhaize Unilever Best Investor Event ASR Nederland Royal Ahold Delhaize Shell Best IR Website AkzoNobel KPN Philips Most Improved Company (IR Programme) Adyen Corbion Exor Young IR Talent Valentina Fantigrossi, ASM International Lennart Scholtus, Heineken Company Thomas Turnock, NN Group The Dutch IR Awards celebrates the achievements of individuals and companies of Dutch stock-listed companies across nine categories; ranging from Best IR professional and Company, to Best Investor Event. The nominations for the Dutch IR Awards are based on European research by Extel and incorporate feedback from global buy and sell-side professionals. The 2025 awards ceremony will be held on Thursday, July 3 in Amsterdam. SPONSORS We would like to extend our gratitude to our 2025 Dutch IR Awards sponsors: Platinum: ABN AMRO and ODDO BHF, CMi2i, Computershare Georgeson, Euronext Corporate Solutions, Ingage, ING Gold: FGS Global, Nasdaq, Notified Silver: S&P Global Market Intelligence, Tangelo Sponsoring through services / products: Extel and NFGD The publication of this press release has been made possible by GlobeNewswire. For media enquiries: Heather Robertson and Jonathan Berger secretariaat@ About the NEVIR: The Netherlands Association for Investor Relations (NEVIR), is the professional representative body and advocacy organisation for all members of Investor Relations teams at Dutch listed companies and consultants in the field of Investor in to access your portfolio
Korea Herald
12-06-2025
- Health
- Korea Herald
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." Worsening patient outcomes because of care delays call for accelerated AI adoption About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days. Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times. AI has the potential to transform care delivery and significantly improve patient outcomes across APAC. Workforce challenge and data burdens call for AI relief Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago. These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden. [1] About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented: Addressing AI concerns from HCPs and patients crucial for widespread adoption A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes. Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%). Trust key to transforming healthcare in APAC For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area. For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%). Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies. "It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems." For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips. About the Future Health Index 2025 The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at
Yahoo
12-06-2025
- Health
- Yahoo
Philips Future Health Index 2025: Delayed care and lost clinical time call for accelerated AI adoption in APAC
66% of patients surveyed in APAC are experiencing delays in seeing specialist doctor, with an average waiting time of 47 days 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions Building trust among patients and healthcare professionals around AI key to driving wider adoption SINGAPORE, June 12, 2025 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today released the Asia Pacific (APAC) findings from its 10th annual Future Health Index (FHI) report, the largest global healthcare survey of its kind. The report draws insights on key concerns from healthcare professionals and patients in 16 countries, including Australia, Indonesia, and South Korea. Findings show that despite strong optimism about artificial intelligence's (AI) potential to ease pressure on APAC's healthcare systems, trust and implementation concerns persist. "The need for AI has never been greater. Our survey shows that patients are anxiously waiting more than a month for specialist care, while some healthcare professionals are losing about four working weeks of clinical time a year due to incomplete patient data," said Jasper Westerink, Senior Vice President and Representative Director of Philips Japan and Acting Managing Director of Philips APAC. "There is a clear role for AI to help clinicians act faster, make better decisions, and anticipate patient needs earlier as we strive to deliver better care for more people." Worsening patient outcomes because of care delays call for accelerated AI adoption About two in three patients (66%) surveyed in APAC are waiting nearly one and a half months to see a specialist doctor, with an average waiting time of 47 days. Generally, one in three patients (33%) in APAC report that their health has deteriorated due to delays in seeing a doctor, with one in four (25%) ultimately going to the hospital as a result of long waiting times. AI has the potential to transform care delivery and significantly improve patient outcomes across APAC. 81% of healthcare professionals in APAC believe that digital health technologies, including AI and predictive analytics, will lead to a reduction in hospital admissions in the future. 86% of healthcare professionals anticipate that these technologies will decrease the need for acute or emergency medical procedures and interventions. 89% of healthcare professionals believe that AI and predictive analytics can save lives by facilitating earlier interventions. Workforce challenge and data burdens call for AI relief Three in four healthcare professionals (76%) in APAC report losing valuable clinical time due to incomplete or inaccessible patient data, with close to one-third (31%) of these losing over 45 minutes per shift, adding up to 23 full days a year lost by each professional. Similarly, two in five (39%) clinicians say they are now spending less time with patients and more time on administrative tasks than they were five years ago. These exacerbate the workforce challenge experienced by healthcare professionals in APAC, as estimated by the World Health Organization. The shortage of health workers in Southeast Asia alone will be 6.9 million respectively in 2030, nearly 40% of the global shortage burden.[1] About 300 healthcare professionals surveyed shared the following concerns if AI is not implemented: 45% worry about an expanding patient backlog 42% cite growing burnout from non-clinical tasks 40% worry about their inability to provide cutting-edge care Addressing AI concerns from HCPs and patients crucial for widespread adoption A majority of healthcare professionals (81%) in APAC are involved in developing new technology at their organizations. However, 39% believe that the new technologies developed are not catered to their needs. Concerns around accountability persist, with 71% sharing concerns about the legal liability for AI usage, while 66% worry that potential data biases in AI applications could widen disparities in health outcomes. Among patients, a majority (75%) welcome the increased use of technology if it improves access to care and benefits them. Around half are concerned that it could reduce face-to-face time with their doctors (51%) and are worried about data security when new technologies are introduced in healthcare (54%). Trust key to transforming healthcare in APAC For the majority of healthcare professionals surveyed (84%) building trust in AI has to involve support with guidelines, issues and liability. In addition, healthcare professionals cite the development of evidence-based, transparent, and monitored AI solutions (72%), followed by reassurance on data security issues, with 51% of healthcare professionals seeking clarity in this area. For patients, about three in four (74%) welcome the use of more technology in healthcare if it helps make it easier to see a healthcare professional and if it helps improve care for patients like themselves (75%). Healthcare professionals play a key role in building trust between patients and AI. Majority of patients (86%) would feel more comfortable with AI in healthcare if hearing about it from their doctors, indicating that doctors are a trusted source of information about such technologies. "It's essential to foster trust of AI-powered technologies among healthcare professionals and patients," said Jasper. "This will enable widespread adoption and effective implementation. Industry-wide collaboration will help us address trust gaps to unlock AI's full potential, enabling responsible, inclusive integration across APAC's healthcare systems." For details on the Future Health Index methodology and to access the full Future Health Index 2025 report, visit Future Health Index | Philips. About the Future Health Index 2025 The Future Health Index is the largest global survey of its kind, analyzing the priorities and perspectives of healthcare professionals and patients across multiple countries. The Future Health Index 2025 investigates how innovative technologies, particularly AI, can empower healthcare professionals to deliver better care to more people. For more information, or to download the full FHI 2025 Global Report, visit About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at [1] Global strategy on human resources for health: workforce 2030. 2016 Geneva World Health Organization View original content to download multimedia: SOURCE Royal Philips Sign in to access your portfolio
Associated Press
11-06-2025
- Business
- Associated Press
Wolters Kluwer completes acquisition of Brightflag
PRESS RELEASE Wolters Kluwer completes acquisition of Brightflag Alphen aan den Rijn — June 11, 2025 — Wolters Kluwer Legal & Regulatory has today completed the previously announced acquisition of Brightflag, a global provider of legal spend and matter management software. The agreement was originally signed and announced on May 29, 2025. ### About Wolters Kluwer Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2024 annual revenues of €5.9 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX, Euro Stoxx 50 and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). For more information, visit follow us on LinkedIn, Facebook, YouTube and Instagram. About Brightflag Brightflag's AI-powered enterprise legal management (ELM) platform provides Chief Legal Officers, General Counsel, and heads of legal operations with visibility into work and spend, tools that improve productivity, and insights needed to operate strategically. Brightflag customers benefit from automatic monthly software updates and a proactive, consultative customer service team whose mission is to make them better month after month and year after year. Forward-looking Statements and Other Important Legal Information This report contains forward-looking statements. These statements may be identified by words such as 'expect', 'should', 'could', 'shall' and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include, without limitation, general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; conditions created by pandemics; behavior of customers, suppliers, and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal, tax, and regulatory rules affecting Wolters Kluwer's businesses, as well as risks related to mergers, acquisitions, and divestments. In addition, financial risks such as currency movements, interest rate fluctuations, liquidity, and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Elements of this press release contain or may contain inside information about Wolters Kluwer within the meaning of Article 7(1) of the Market Abuse Regulation (596/2014/EU). Trademarks referenced are owned by Wolters Kluwer N.V. and its subsidiaries and may be registered in various countries. Attachment
